Analyst consensus rating
Climb Bio Analyst Rating: Strong Buy
Direct answer
Climb Bio's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.87.
Forecast evidence checked October 27, 2026.
Get free Climb Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.57
- Average price target
- $27.87
- High price target
- $40.00
- Low price target
- $18.00
- Low target gap
- +88.1%
- Target upside
- +191.2%
- High target gap
- +318%
- Target range width
- 229.9%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Climb Bio?
Climb Bio has a verified Strong Buy consensus. The same dataset has an average price target of $27.87.
How far are Climb Bio's low and high targets from the recorded price?
The low target implies +88.1%, while the high target implies +318%.
How many analysts are included in Climb Bio's consensus?
The verified consensus includes 15 analysts.
How is Climb Bio's target upside or downside calculated?
The average target of $27.87 is divided by the recorded price of $9.57, then one is subtracted to produce +191.2%. This does not guarantee a future return.
When was Climb Bio's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.